Thymidine Labeling Index Analysis in Early Breast Cancer Patients Randomized to Receive Perioperative Chemotherapy

Oncology ◽  
2000 ◽  
Vol 60 (1) ◽  
pp. 88-93 ◽  
Author(s):  
Paolo Pronzato ◽  
Paola Queirolo ◽  
Stefania Vecchio ◽  
Rita Lionetto ◽  
Lucia Del Mastro ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Early Breast Cancer ◽  
Labeling Index ◽  
Perioperative Chemotherapy ◽  
Breast Cancer Patients ◽  
Index Analysis ◽  
Thymidine Labeling Index ◽  
To Receive

Impact of Five Prophylactic Filgrastim Schedules on Hematologic Toxicity in Early Breast Cancer Patients Treated With Epirubicin and Cyclophosphamide

2005 ◽  
Vol 23 (28) ◽  
pp. 6908-6918 ◽  
Author(s):  
Paola Papaldo ◽  
Massimo Lopez ◽  
Paolo Marolla ◽  
Enrico Cortesi ◽  
Mauro Antimi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Early Breast Cancer ◽  
Dose Intensity ◽  
High Dose ◽  
Hematologic Toxicity ◽  
Breast Cancer Patients ◽  
Nonrandomized Trial ◽  
Grade 3 ◽  
To Receive

Purpose To evaluate the comparative efficacy of varying intensity schedules of recombinant human granulocyte colony-stimulating factor (G-CSF; filgrastim) support in preventing febrile neutropenia in early breast cancer patients treated with relatively high-dose epirubicin plus cyclophosphamide (EC). Patients and Methods From October 1991 to April 1994, 506 stage I and II breast cancer patients were randomly assigned to receive, in a factorial 2 × 2 design, epirubicin 120 mg/m2 and cyclophosphamide 600 mg/m2 intravenously on day 1 every 21 days for 4 cycles ± lonidamine ± G-CSF. The following five consecutive G-CSF schedules were tested every 100 randomly assigned patients: (1) 480 μg/d subcutaneously days 8 to 14; (2) 480 μg/d days 8, 10, 12, and 14; (3) 300 μg/d days 8 to 14; (4) 300 μg/d days 8, 10, 12, and 14; and (5) 300 μg/d days 8 and 12. Results All of the G-CSF schedules covered the neutrophil nadir time. Schedule 5 was equivalent to the daily schedules (schedules 1 and 3) and to the alternate day schedules (schedules 2 and 4) with respect to incidence of grade 3 and 4 neutropenia (P = .79 and P = .89, respectively), rate of fever episodes (P = .84 and P = .77, respectively), incidence of neutropenic fever (P = .74 and P = .56, respectively), need of antibiotics (P = .77 and P = .88, respectively), and percentage of delayed cycles (P = .43 and P = .42, respectively). G-CSF had no significant impact on the delivered dose-intensity compared with the non–G-CSF arms. Conclusion In the adjuvant setting, the frequency of prophylactic G-CSF administration during EC could be curtailed to only two administrations (days 8 and 12) without altering outcome. This nonrandomized trial design provides support for evaluating alternative, less intense G-CSF schedules for women with early breast cancer.

Improved survival after one course of perioperative chemotherapy in early breast cancer patients

2001 ◽  
Vol 37 (17) ◽  
pp. 2184-2193 ◽  
Author(s):  
J.A van der Hage ◽  
C.J.H van de Velde ◽  
J.-P Julien ◽  
J.-L Floiras ◽  
T Delozier ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Early Breast Cancer ◽  
Perioperative Chemotherapy ◽  
Breast Cancer Patients

CD1a- and CD83-positive dendritic cells as prognostic markers of metastasis development in early breast cancer patients

Breast Cancer ◽  
2021 ◽  
Author(s):  
María Belén Giorello ◽  
Ayelén Matas ◽  
Pablo Marenco ◽  
Kevin Mauro Davies ◽  
Francisco Raúl Borzone ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Dendritic Cells ◽  
Cancer Patients ◽  
Early Breast Cancer ◽  
Prognostic Markers ◽  
Breast Cancer Patients ◽  
Metastasis Development
Sign in / Sign up

Export Citation Format

Share Document